Revenue (Annual)

Revenue: The sum of all revenue fields included for a company's operating activities.

Basilea Pharmaceutica AG (BPMUF) had Revenue of $236.88M for the most recently reported fiscal year, ending 2024-12-31.

Quarterly Annual

Figures for fiscal year ending 2024-12-31

Income Statement Financials
Revenue	$236.88M
Net Income	$88.14M
Cost of Goods Sold	$43.94M
Gross Profit	$192.95M
Operating Expenses	$167.39M
Operating Income	$69.49M
Non-Operating Income/Expense	$-1.04M
Pre-Tax Income	$68.45M
Normalized Pre-Tax Income	$68.45M
Income after Taxes	$88.14M
Income from Continuous Operations	$88.14M
Consolidated Net Income/Loss	$88.14M
Normalized Income after Taxes	$88.14M
EBIT	$69.49M
EBITDA	$71.46M
Weighted-Average Shares Outstanding (Basic)	12.09M
Weighted-Average Shares Outstanding (Diluted)	13.86M
Earnings per Share (EPS) (Basic)	$7.29
Earnings per Share (EPS) (Diluted)	$6.62
Balance Sheet Financials
Current Assets	$250.93M
Property, Plant, and Equipment	$4.55M
Long-Term Assets	$41.86M
Total Assets	$292.79M
Current Liabilities	$51.75M
Long-Term Debt	$108.95M
Long-Term Liabilities	$149.04M
Total Liabilities	$200.79M
Common Equity	$92.01M
Tangible Shareholders Equity	$91.58M
Shareholders Equity	$92.01M
Common Shares Outstanding	11.05M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$84.47M
Cash Flow from Investing Activities	$-1.15M
Cash Flow from Financial Activities	$-14.95M
Beginning Cash	$73.06M
End Cash	$141.49M
Increase/Decrease in Cash	$68.42M
Stock-Based Compensation	$5.75M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	4.85
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.54
Debt to Equity Ratio	1.18
Gross Margin	81.45%
Operating Margin	29.34%
EBIT Margin	29.34%
EBITDA Margin	30.17%
Pre-Tax Profit Margin	28.90%
Profit Margin	37.21%
Free Cash Flow	$82.53M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.81
Inventory Turnover	1.22
Receiveable Turnover	3.58
Days Sales in Receivables	101.83
Return on Equity	95.79%
Return on Tangible Equity	96.24%
Return on Assets	30.10%
Return on Investments	43.86%
Book Value Per Share	$8.33
Free Cash Flow per Share	$5.96
Operating Cash Flow per Share	$6.10

Data from Zacks Investment Research, Inc.